These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 31379105)

  • 1. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
    Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
    Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
    Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
    Danlos FX; Voisin AL; Dyevre V; Michot JM; Routier E; Taillade L; Champiat S; Aspeslagh S; Haroche J; Albiges L; Massard C; Girard N; Dalle S; Besse B; Laghouati S; Soria JC; Mateus C; Robert C; Lanoy E; Marabelle A; Lambotte O
    Eur J Cancer; 2018 Mar; 91():21-29. PubMed ID: 29331748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
    Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
    Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology.
    Hoa S; Laaouad L; Roberts J; Ennis D; Ye C; Al Jumaily K; Pope J; Nevskaya T; Saltman A; Himmel M; Rottapel R; Ly C; Colmegna I; Fifi-Mah A; Maltez N; Tisseverasinghe A; Hudson M; Jamal S
    Cancer Immunol Immunother; 2021 Aug; 70(8):2197-2207. PubMed ID: 33471137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.
    Richter MD; Pinkston O; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
    Arthritis Rheumatol; 2018 Mar; 70(3):356-360. PubMed ID: 29363290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
    Fountzilas E; Lampaki S; Koliou GA; Koumarianou A; Levva S; Vagionas A; Christopoulou A; Laloysis A; Psyrri A; Binas I; Mountzios G; Kentepozidis N; Kotsakis A; Saloustros E; Boutis A; Nikolaidi A; Fountzilas G; Georgoulias V; Chrysanthidis M; Kotteas E; Vo H; Tsiatas M; Res E; Linardou H; Daoussis D; Bompolaki I; Andreadou A; Papaxoinis G; Spyratos D; Gogas H; Syrigos KN; Bafaloukos D
    Cancer Immunol Immunother; 2022 Feb; 71(2):327-337. PubMed ID: 34164709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
    Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
    Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
    Kennedy LC; Bhatia S; Thompson JA; Grivas P
    J Natl Compr Canc Netw; 2019 Jun; 17(6):750-757. PubMed ID: 31200356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
    van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
    Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
    Johnson DB; Sullivan RJ; Ott PA; Carlino MS; Khushalani NI; Ye F; Guminski A; Puzanov I; Lawrence DP; Buchbinder EI; Mudigonda T; Spencer K; Bender C; Lee J; Kaufman HL; Menzies AM; Hassel JC; Mehnert JM; Sosman JA; Long GV; Clark JI
    JAMA Oncol; 2016 Feb; 2(2):234-40. PubMed ID: 26633184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
    Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
    Kumar R; Chan A; Bandikatla S; Ranjan S; Ngo P
    Curr Probl Cancer; 2022 Aug; 46(4):100864. PubMed ID: 35671576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression.
    Sparks JA
    Rheum Dis Clin North Am; 2024 May; 50(2):147-159. PubMed ID: 38670718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.